ProShare Advisors’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.11M | Sell |
3,520
-390
| -10% | -$91.9K | ﹤0.01% | 772 |
|
|
2026
Q1 | $781K | Sell |
3,910
-730
| -16% | -$144K | ﹤0.01% | 870 |
|
|
2025
Q4 | $877K | Buy |
4,640
+339
| +8% | +$65.1K | ﹤0.01% | 862 |
|
|
2025
Q3 | $762K | Sell |
4,301
-680
| -14% | -$101K | ﹤0.01% | 906 |
|
|
2025
Q2 | $566K | Sell |
4,981
-124
| -2% | -$13.3K | ﹤0.01% | 1057 |
|
|
2025
Q1 | $537K | Sell |
5,105
-1,039
| -17% | -$117K | ﹤0.01% | 1055 |
|
|
2024
Q4 | $658K | Buy |
6,144
+1,490
| +32% | +$168K | ﹤0.01% | 1116 |
|
|
2024
Q3 | $466K | Buy |
4,654
+951
| +26% | +$95.7K | ﹤0.01% | 1178 |
|
|
2024
Q2 | $312K | Sell |
3,703
-924
| -20% | -$73.5K | ﹤0.01% | 1266 |
|
|
2024
Q1 | $338K | Buy |
4,627
+363
| +9% | +$26.8K | ﹤0.01% | 1355 |
|
|
2023
Q4 | $305K | Buy |
4,264
+599
| +16% | +$35.3K | ﹤0.01% | 1363 |
|
|
2023
Q3 | $220K | Sell |
3,665
-49
| -1% | -$3.23K | ﹤0.01% | 1405 |
|
|
2023
Q2 | $268K | Buy |
3,714
+312
| +9% | +$23.4K | ﹤0.01% | 1345 |
|
|
2023
Q1 | $250K | Sell |
3,402
-409
| -11% | -$29.1K | ﹤0.01% | 1308 |
|
|
2022
Q4 | $255K | Sell |
3,811
-1,843
| -33% | -$120K | ﹤0.01% | 1330 |
|
|
2022
Q3 | $304K | Buy |
5,654
+48
| +0.9% | +$2.82K | ﹤0.01% | 1142 |
|
|
2022
Q2 | $311K | Sell |
5,606
-2,656
| -32% | -$151K | ﹤0.01% | 1203 |
|
|
2022
Q1 | $580K | Sell |
8,262
-1,633
| -17% | -$118K | ﹤0.01% | 1191 |
|
|
2021
Q4 | $953K | Buy |
9,895
+392
| +4% | +$36.2K | ﹤0.01% | 1049 |
|
|
2021
Q3 | $826K | Sell |
9,503
-3,579
| -27% | -$277K | ﹤0.01% | 972 |
|
|
2021
Q2 | $1.07M | Buy |
13,082
+1,172
| +10% | +$97.5K | ﹤0.01% | 1003 |
|
|
2021
Q1 | $1.13M | Buy |
11,910
+798
| +7% | +$75.4K | ﹤0.01% | 916 |
|
|
2020
Q4 | $689K | Buy |
11,112
+2,384
| +27% | +$136K | ﹤0.01% | 1073 |
|
|
2020
Q3 | $519K | Sell |
8,728
-223
| -2% | -$15.2K | ﹤0.01% | 927 |
|
|
2020
Q2 | $625K | Buy |
8,951
+2,444
| +38% | +$155K | ﹤0.01% | 858 |
|
|
2020
Q1 | $295K | Sell |
6,507
-5,687
| -47% | -$322K | ﹤0.01% | 880 |
|
|
2019
Q4 | $793K | Sell |
12,194
-1,736
| -12% | -$116K | ﹤0.01% | 882 |
|
|
2019
Q3 | $865K | Sell |
13,930
-2,042
| -13% | -$128K | ﹤0.01% | 795 |
|
|
2019
Q2 | $1.14M | Sell |
15,972
-2,828
| -15% | -$208K | 0.01% | 719 |
|
|
2019
Q1 | $1.47M | Buy |
18,800
+458
| +2% | +$34.7K | 0.01% | 664 |
|
|
2018
Q4 | $1.55M | Sell |
18,342
-1,607
| -8% | -$171K | 0.01% | 621 |
|
|
2018
Q3 | $3.42M | Sell |
19,949
-749
| -4% | -$113K | 0.02% | 509 |
|
|
2018
Q2 | $2.67M | Sell |
20,698
-1,056
| -5% | -$118K | 0.02% | 563 |
|
|
2018
Q1 | $2.24M | Sell |
21,754
-3,293
| -13% | -$326K | 0.01% | 595 |
|
|
2017
Q4 | $2.14M | Buy |
25,047
+2,332
| +10% | +$202K | 0.01% | 590 |
|
|
2017
Q3 | $1.93M | Buy |
22,715
+1,442
| +7% | +$114K | 0.02% | 571 |
|
|
2017
Q2 | $1.61M | Sell |
21,273
-1,496
| -7% | -$105K | 0.02% | 607 |
|
|
2017
Q1 | $1.5M | Sell |
22,769
-5,383
| -19% | -$354K | 0.02% | 632 |
|
|
2016
Q4 | $1.78M | Buy |
28,152
+2,575
| +10% | +$162K | 0.02% | 583 |
|
|
2016
Q3 | $1.63M | Sell |
25,577
-3,676
| -13% | -$270K | 0.02% | 546 |
|
|
2016
Q2 | $2.18M | Buy |
29,253
+505
| +2% | +$37.5K | 0.03% | 474 |
|
|
2016
Q1 | $1.92M | Sell |
28,748
-1,751
| -6% | -$106K | 0.03% | 469 |
|
|
2015
Q4 | $2.06M | Buy |
30,499
+2,996
| +11% | +$185K | 0.03% | 497 |
|
|
2015
Q3 | $1.47M | Sell |
27,503
-1,755
| -6% | -$106K | 0.02% | 567 |
|
|
2015
Q2 | $1.84M | Sell |
29,258
-2,879
| -9% | -$157K | 0.03% | 543 |
|
|
2015
Q1 | $1.55M | Buy |
32,137
+3,368
| +12% | +$129K | 0.02% | 645 |
|
|
2014
Q4 | $955K | Sell |
28,769
-2,379
| -8% | -$77.4K | 0.01% | 877 |
|
|
2014
Q3 | $913K | Sell |
31,148
-6,540
| -17% | -$217K | 0.01% | 1104 |
|
|
2014
Q2 | $1.47M | Sell |
37,688
-17,237
| -31% | -$699K | 0.02% | 970 |
|
|
2014
Q1 | $2.31M | Buy |
54,925
+38,118
| +227% | +$1.59M | 0.03% | 659 |
|
|
2013
Q4 | $552K | Sell |
16,807
-12,743
| -43% | -$415K | 0.01% | 1059 |
|
|
2013
Q3 | $798K | Buy |
29,550
+5,205
| +21% | +$146K | 0.02% | 1045 |
|
|
2013
Q2 | $568K | Buy |
+24,345
| New | +$438K | 0.01% | 1232 |
|
Other funds holding LGND
JT
CAM
ProShare Advisors's LGND Position: Q2 2026 in Review
ProShare Advisors reduced its Ligand Pharmaceuticals (LGND) stake by 10% in Q2 2026, selling an estimated $91.9K and leaving 3,520 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #772.
ProShare Advisors first reported a position in LGND in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.42M in Q3 2018. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- ProShare Advisors held 3,520 shares of Ligand Pharmaceuticals worth $1.11M as of Q2 2026.
- ProShare Advisors sold 390 Ligand Pharmaceuticals shares in Q2 2026, an estimated $91.9K.
- Ligand Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #772 holding.
- ProShare Advisors first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- ProShare Advisors's Ligand Pharmaceuticals position peaked at $3.42M in Q3 2018.
- 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.